FILTER

FILTERED INTERVIEW RESULTS

United States
Pharma & Life Sciences

Michael Quirmbach

CEO AND PRESIDENT, CORDENPHARMA
"Our main mission is the execution of a >€200 million investment into CapEx projects that will bring additional capacity and technologies online to support pharma and biotech customers as their drug development projects progress."
United States
Pharma & Life Sciences

Christiana Bardon

CO-MANAGING PARTNER, MPM | BIOIMPACT CAPITAL
"We see this as an exciting time to be investing in record-high levels of innovation at very attractive valuations."
United States
Pharma & Life Sciences

Debbie Hart

PRESIDENT AND CEO, BIONJ
"To ensure that New Jersey maintains this leadership position, BioNJ will continue to work with State government to support industry and stave off onerous proposals. "
United States
Pharma & Life Sciences

Jay Shukla

PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS, INC.
"Our partners benefit from our market intelligence and cost-splitting, and we attain the manufacturing capability and resources. We will continue to grow our partnership model now that we are expecting to double our revenue."
United States
Pharma & Life Sciences

Robert Poe

CEO, OLON RICERCA BIOSCIENCES
"What we are doing here is beginning the build-out of a high-potency API suite, so that we can get up to a few hundred grams made for early studies and transfer those processes to our sites in Italy for the clinical trial phase."
United States
Pharma & Life Sciences

Manni Kantipudi & Ramesh Subramanian

CHIEF EXECUTIVE OFFICER (MK) & CHIEF COMMERCIAL OFFICER (RS), ARAGEN LIFE SCIENCES
"Overall, I believe the virtual biotech model is here to stay and companies will increasingly look at CRO/CDMO companies for assistance in taking drugs from discovery to commercialization."
United States
Pharma & Life Sciences

Chris Garabedian

CHAIRMAN AND CEO, XONTOGENY, AND PORTFOLIO MANAGER, PERCEPTIVE XONTOGENY VENTURE (PXV) FUND
"Following a long period of significant investment in early-stage firms, our industry needs to allow existing investments across the industry to mature and show signs of success before driving new investments in preclinical-stage projects."
Mining
United States

Jeff Olsen

CEO, BOART LONGYEAR
"I believe the increased drilling activity will continue into 2023, and we are anticipating strong business for the foreseeable future."
Mining
United States

Keith Jones

GENERAL MANAGER, SMALL MINE DEVELOPMENT (SMD)
"We are open to working anywhere in the US where there are hard rock, metal, or non-metal, underground mines."
United States
Pharma & Life Sciences

Tom Wilson

GLOBAL BUSINESS DEVELOPMENT LEAD, PFIZER CENTREONE
"As we get into precision medicines, therapies, parallel trials, and getting medicines to patients faster, that will require CDMOs to work together, and this is where our growth will come from."

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL